The Company now concentrates its activities in the field of oncology through the development of Chimeric Antigen Receptor T-cell immunotherapy products generated through its allogeneic CAR-T platform, both on its own as well as in partnership with is a biotechnology company focused on applications of human embryonic stem cell based products and ... (more)
http://ift.tt/1AA70Ww
http://ift.tt/1AA70Ww
No comments:
Post a Comment